Literature DB >> 27861725

PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.

Mizuki Nishino1, Nikhil H Ramaiya1, Hiroto Hatabu1, F Stephen Hodi2, Philippe F Armand2.   

Abstract

Entities:  

Keywords:  PD-1 inhibitor; immune-related adverse event; lymphoma; pembrolizumab; pneumonitis

Mesh:

Substances:

Year:  2016        PMID: 27861725     DOI: 10.1111/bjh.14441

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.

Authors:  Sawsan Rashdan; John D Minna; David E Gerber
Journal:  Lancet Respir Med       Date:  2018-06       Impact factor: 30.700

Review 2.  Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Authors:  Mizuki Nishino; Hiroto Hatabu; Lynette M Sholl; Nikhil H Ramaiya
Journal:  Radiographics       Date:  2017 Sep-Oct       Impact factor: 5.333

3.  Progressive Pulmonary Infiltrates in a Man with Mediastinal Lymphoma.

Authors:  Carla S Walti; Guang-Shing Cheng; Ajay K Gopal; Joshua A Hill
Journal:  Ann Am Thorac Soc       Date:  2021-05

Review 4.  PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis.

Authors:  Jiaying Wu; Dongsheng Hong; Xiangnan Zhang; Xiaoyang Lu; Jing Miao
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

Review 5.  Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment: Three case reports and literature review.

Authors:  Jiho Jun; Sang-Ryung Lee; Ji Yean Lee; Min Joo Choi; Ji Yun Noh; Hee Jin Cheong; Woo Joo Kim; Joon Young Song
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

6.  Comparison of Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) and Pneumonia Associated with Lymphoma.

Authors:  Shuting Wang; Yinshi Zheng; Zhaoqi Wang; Xiaoqiang Yao; Bei Dong; Huan Liu; Jinrong Qu
Journal:  Int J Med Sci       Date:  2020-07-19       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.